Baird Downgrades Nivalis Therapeutics (NVLS) to Neutral Following Clinical Failure

November 29, 2016 6:14 AM EST Send to a Friend
Baird downgraded Nivalis Therapeutics (NASDAQ: NVLS) from Outperform to Neutral with a price target of $3.00 (from $29.00) after clinical ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login